FN2 Earnings Intelligence
Axsome Therapeutics, Inc. financials
Axsome Therapeutics, Inc. (AXSM) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $86.5 | $200.8 | $386.2 | $315.4 | $322.9 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | - | $0 | $270.6 | $385.7 | $638.5 |
| % Growth | - | - | - | 42.5% | 65.5% |
| Gross Profit | - | -$5.2 | $244.5 | - | - |
| % Margin | - | - | 90.4% | - | - |
| EBITDA | -$124.6 | -$179.5 | -$231.4 | -$280 | -$166.3 |
| % Margin | - | - | -85.5% | -72.6% | -26.0% |
| Net Income | -$130.4 | -$187.1 | -$239.2 | -$287.2 | -$183.2 |
| % Margin | - | - | -88.4% | -74.5% | -28.7% |
| Diluted EPS | - | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
| % Growth | - | - | -14.6% | -13.7% | 38.6% |
| Operating Cash Flow | -$108.2 | -$116.5 | -$145.1 | -$128.4 | -$93.4 |
| CapEx | $0.3 | $0.7 | $0.6 | $0.3 | $0.5 |
| Free Cash Flow | -$108.5 | -$117.2 | -$145.7 | -$128.7 | -$93.9 |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue | - | $0 | $270.6 | $385.7 | $638.5 |
| Gross Profit | - | -$5.2 | $244.5 | - | - |
| EBITDA | -$124.6 | -$179.5 | -$231.4 | -$280 | -$166.3 |
| Net Income | -$130.4 | -$187.1 | -$239.2 | -$287.2 | -$183.2 |
| Diluted EPS | - | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $86.5 | $200.8 | $386.2 | $315.4 | $322.9 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $49.1 | $94.3 | $178.1 | $180.7 | $117.7 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$108.2 | -$116.5 | -$145.1 | -$128.4 | -$93.4 |
| Capital Expenditure | $0.3 | $0.7 | $0.6 | $0.3 | $0.5 |
| Free Cash Flow | -$108.5 | -$117.2 | -$145.7 | -$128.7 | -$93.9 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 42.5% | 65.5% |
| Gross Margin | - | - | 90.4% | - | - |
| EBITDA Margin | - | - | -85.5% | -72.6% | -26.0% |
| Net Margin | - | - | -88.4% | -74.5% | -28.7% |
| FCF Margin | - | - | -53.8% | -33.4% | -14.7% |
| Diluted EPS Growth | - | - | -14.6% | -13.7% | 38.6% |
Get the AXSM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.